A Phase II Trial of Dexamethasone and 13-cis-Retinoic Acid as First-Line Treatment for Multiple Myeloma

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed multiple myeloma Elevated monoclonal
protein in serum and/or urine

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:
Not specified Hematopoietic: WBC at least 3,000/mm3* Platelet count at least 75,000/mm3*
*Unless secondary to multiple myeloma involvement of the bone marrow Hepatic: Bilirubin
less than 1.5 mg/dL Transaminase less than 2 times normal Renal: Creatinine less than 2.0
mg/dL No overt renal insufficiency Cardiovascular: No congestive heart failure No
myocardial infarction within the past 6 months No significant arrhythmia or poorly
controlled hypertension Pulmonary: No severe pulmonary disease Other: Triglycerides normal
No other severe medical illness No active peptic ulcer disease No brittle
insulin-dependent diabetes No severe depression or other psychiatric illness No active
infection No history of severe ethanol or drug abuse Not pregnant or nursing Negative
pregnancy test Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy Endocrine therapy: Not specified Radiotherapy: Prior palliative radiotherapy
allowed Surgery: At least 3 weeks since prior major surgery